Effects of 5 years of treatment with rabeprazole or omeprazole on the gastric mucosa

European Journal of Gastroenterology and Hepatology

Volumn 17, Issue 5, 2005, Pages 559-566

  Rindi, Guido ^a   Fiocca, Roberto ^b   Morocutti, Anna ^c   Jacobs, Adam ^d   Miller, Neil ^c   Thjodleifsson, Bjarni ^e  

^a UNIVERSITY OF PARMA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c EISAI CO LTD   (Japan)

^d Dianthus Medical Limited   (United Kingdom)

^e LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

Author keywords

Biopsy; Enterochromaffin like cells; Gastric mucosa; Gastrins; Gastritis; Helicobacter pylori; Omeprazole; Rabeprazole

Indexed keywords

OMEPRAZOLE; RABEPRAZOLE;

ARTICLE; CELL HYPERPLASIA; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DYSPLASIA; ENTEROCHROMAFFIN CELL; GASTRIN BLOOD LEVEL; GASTRITIS; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; STATISTICAL SIGNIFICANCE; STOMACH BIOPSY; STOMACH MUCOSA; STOMACH TUMOR;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGED; ANTI-ULCER AGENTS; BENZIMIDAZOLES; BIOPSY; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GASTRIC MUCOSA; GASTRINS; GASTRITIS; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; HYPERPLASIA; MALE; METAPLASIA; MIDDLE AGED; OMEPRAZOLE; PROSPECTIVE STUDIES; PROTON PUMPS; SEVERITY OF ILLNESS INDEX;

EID: 17844368379     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200505000-00013     Document Type: Article

References (28)

1. Isolauri J, Luostarinen M, Isolauri E, Reinikainen P, Viljakka M, Keyrilainen O. Natural course of gastroesophageal reflux disease: 17-22 year follow-up of 60 patients. Am J Gastroenterol 1997; 92:37-41.
2. Dent J. Management of reflux disease. Gut 2002; 50 (suppl 4):iv67-iv71.
3. Dent J, Jones R, Kahrilas P, Talley NJ. Management of gastro-oesophageal reflux disease in general practice. BMJ 2001; 322:344-347.
4. McDougall NI, Johnston BT, Collins JS, McFarland RJ, Love AH. Three to 4.5-year prospective study of prognostic indicators in gastro-oesophageal reflux disease. Scand J Gastroenterol 1998; 33:1016-1022.
5. Pohle T, Domschke W. Results of short- and long-term medical treatment of gastroesophageal reflux disease (GERD). Langenbecks Arch Surg 2000; 385:317-323.
6. Freston JW. Long-term acid control and proton pump inhibitors: interactions and safety issues in perspective. Am J Gastroenterol 1997; 92:51S-55S; discussion 55S-57S.
7. Thjodleifsson B, Rindi G, Fiocca R, Humphries TJ, Morocutti A, Miller N, et al. A randomized, double-blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro oesophageal reflux disease over 5 years. Aliment Pharmacol Ther 2003; 17:343-351.
8. Koop H, Klein M, Arnold R. Serum gastrin levels during long-term omeprazole treatment Aliment Pharmacol Ther 1990; 4:131-138.
9. Bardhan KD, Cherian P, Bishop AE, Polak JM, Romanska H, Perry MJ, et al. Pantoprazole therapy in the long-term management of severe acid peptic disease: clinical efficacy, safety, serum gastrin, gastric histology, and endocrine cell studies. Am J Gastroenterol 2001; 96:1767-1776.
10. McGuigan JE. Zollinger-Ellison syndrome and other hypersecretory states. In: Feldman M, Scharschmidt BF, Sleisenger MH, Klein S (editors): Sleisenger & Fordtran's Gastrointestinal and Liver Disease Pathophysiology/Diagnosis/ Management, 6th edition. Philadelphia: WB Saunders; 1998, pp. 679-695.
11. Dent J. Controversies in long-term management of reflux disease. Baillière's Best Pract Res Clin Gastroenterol 2000; 14:811-826.
12. Lamberts R. Morphological changes of the human gastric mucosa under long-term proton pump inhibitor therapy and their clinical relevance. Microsc Res Tech 2000; 48:357-366.
13. Waldum HL, Brenna E. Personal review: is profound acid inhibition safe? Aliment Pharmacol Ther 2000;14:15-22.
14. Preston JW, Borch K, Brand SJ, Carlsson E, Creutzfeldt W, Hakanson R, et al. Effects of hypochlorhydria and hypergastrinemia on structure and function of gastrointestinal cells. A review and analysis. Dig Dis Sci 1995; 40:50S-62S.
15. McCloy RF, Arnold R, Bardhan KD, Cattan D, Klinkenberg-Knol E, Maton PN, et al. Pathophysiological effects of long-term acid suppression in man. Dig Dis Sci 1995; 40:96S-120S.
16. Peghini PL, Annibale B, Azzoni C, Milione M, Corleto VD, Gibril F, et al. Effect of chronic hypergastrinemia on human enterochromaffin-like cells: insights from patients with sporadic gastrinomas. Gastroenterology 2002; 123:68-85.
17. Reilly JP. Safety profile of the proton-pump inhibitors. Am J Health Syst Pharm 1999; 56:S11-S17.
18. Robinson M. Review article: current perspectives on hypergastrinaemia and enterochromaffin-like-cell hyperplasia. Aliment Pharmacol Ther 1999; 13 (suppl 5):5-10.
19. Yeomans ND, Dent J. Personal review: alarmism or legitimate concerns about long-term suppression of gastric acid secretion? Aliment Pharmacol Ther 2000; 14:267-271.
20. Diebold MD, Richardson S, Duchateau A, et al. Factors influencing corpus argyrophil cell density and hyperplasia in reflux esophagitis patients treated with antisecretory drugs and controls. Dig Dis Sci 1998; 43:1629-1635.
21. Lamberts R, Brunner G, Solcia E. Effects of very long (up to 10 years) proton pump blockade on human gastric mucosa. Digestion 2001; 64: 205-213.
22. Lamberts R, Creutzfeldt W, Struber HG, Brunner G, Solcia E. Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. Gastroenterology 1993; 104:1356-1370.
23. Klinkenberg-Knol EC, Festen HP, Jansen JB, Lamers CB, Nelis F, Snel P, et al. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med 1994; 121:161-167.
24. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, Havu N, Festen HP, Liedman B, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996; 334:1018-1022.
25. Klinkenberg-Knol EC, Nelis F, Dent J, Snel P, Mitchell B, Prichard P, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000; 118:661-669.
26. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996; 20:1161-1181.
27. Solcia E, Bordi C, Creutzfeldt W, Dayal Y, Dayan AD, Falkmer S, et al. Histopathological classification of nonantral gastric endocrine growths in man. Digestion 1988; 41:185-200.
28. Tari A, Kawano M, Kodama K, Yonei Y, Okahara S, Haruma K, et al. The effects of rabeprazole on parietal cells and enterochromaffin-like cells in rats: a comparison with omeprazole. J Gastroenterol 2002; 37: 177-185.